- Home
- CMRC vs NGNE Comparison
CMRC vs NGNE Comparison
Compare CMRC & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMRC
- NGNE
- Stock Information
- Founded
- CMRC 2009
- NGNE 2003
- Country
- CMRC United States
- NGNE United States
- Employees
- CMRC N/A
- NGNE N/A
- Industry
- CMRC
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- CMRC
- NGNE Health Care
- Exchange
- CMRC Nasdaq
- NGNE Nasdaq
- Market Cap
- CMRC 359.6M
- NGNE 325.3M
- IPO Year
- CMRC 2020
- NGNE N/A
- Fundamental
- Price
- CMRC N/A
- NGNE $21.74
- Analyst Decision
- CMRC
- NGNE Strong Buy
- Analyst Count
- CMRC 0
- NGNE 7
- Target Price
- CMRC N/A
- NGNE $41.86
- AVG Volume (30 Days)
- CMRC 1.1M
- NGNE 122.9K
- Earning Date
- CMRC 11-06-2025
- NGNE 08-12-2025
- Dividend Yield
- CMRC N/A
- NGNE N/A
- EPS Growth
- CMRC N/A
- NGNE N/A
- EPS
- CMRC N/A
- NGNE N/A
- Revenue
- CMRC $337,541,000.00
- NGNE $925,000.00
- Revenue This Year
- CMRC N/A
- NGNE N/A
- Revenue Next Year
- CMRC N/A
- NGNE N/A
- P/E Ratio
- CMRC N/A
- NGNE N/A
- Revenue Growth
- CMRC 4.06
- NGNE N/A
- 52 Week Low
- CMRC $4.47
- NGNE $6.88
- 52 Week High
- CMRC $5.27
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- CMRC N/A
- NGNE 54.39
- Support Level
- CMRC N/A
- NGNE $21.16
- Resistance Level
- CMRC N/A
- NGNE $23.80
- Average True Range (ATR)
- CMRC 0.00
- NGNE 1.52
- MACD
- CMRC 0.00
- NGNE -0.18
- Stochastic Oscillator
- CMRC 0.00
- NGNE 33.59
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.